← All trials
NCT05587322
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 6, 2022
- Primary completion
- Jan 26, 2024
- Completion date
- May 31, 2024
- First posted
- Oct 20, 2022
- Last posted
- Oct 20, 2022
- Enrollment
- 633
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Braintree LaboratoriesLead sponsor
- Sebela PharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.